REG - Silence Therapeutics - Director/PDMR Shareholding

Silence TherapeuticsAnnouncement

12/10/2020 15:50

RNS Number : 8322B
  
Silence Therapeutics PLC
  
12 October 2020
  
 

Director Dealing
12 October 2020
 
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that, on the 8th and 9th October 2020, 9,750 Shares were purchased by Iain Ross, Chairman of the Company, through his self-invested personal pension (SIPP) at £4.10 per share, 1,250 Shares were purchased by David Lemus, Non-Executive Director of the Company, at £4.00 per share, 3,000 Shares were purchased by James Ede-Golightly, Non-Executive Director of the Company, at £4.09 per share, and 4,945 Shares were purchased by Dr. Giles Campion, Executive Director of the Company, at £4.04 per share.
 
Following this purchase, Iain Ross is interested in 54,443 ordinary shares (0.07%) of the issued share capital of the Company, David Lemus is interested in 6,876 ordinary shares (0.01%) of the issued share capital of the Company, James Ede-Golightly is interested in 3,000 ordinary shares (0.00%) of the issued share capital of the Company, and Dr. Giles Campion is interested in 14,945 ordinary shares (0.02%) of the issued share capital of the Company.
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
 



1.


Details of the person discharging managerial responsibilities (PDMR) / person closely associated




a)


Name


Iain Ross
 




2.


Reason for the notification




a)


Position / status


Chairman 
 




b)


Initial notification / Amendment


Initial notification




3.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Silence Therapeutics plc
 




b)


LEI


213800SSURRJBX85SQ91
 




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
 
Identification code


Ordinary Shares of 5 pence each in Silence Therapeutics plc
 
 
 
ISIN for Silence Therapeutics plc Ordinary Shares:
GB00B9GTXM62
 




b)


Nature of the transaction


Purchase of Ordinary Shares in Silence Therapeutics plc 
 




c)


Prices(a) and volume(s)


 



Price


Volume




£4.10


9,750



 
 




d)


Aggregated information
- Aggregated volume
- Price


 
9,750 Ordinary Shares
£39,976.00




e)


Date of the transaction


8 October 2020




f)


Place of the transaction


London Stock Exchange, AIM
 



 



1.


Details of the person discharging managerial responsibilities (PDMR) / person closely associated




a)


Name


David Lemus
 




2.


Reason for the notification




a)


Position / status


Non-Executive Director
 




b)


Initial notification / Amendment


Initial notification




3.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Silence Therapeutics plc
 




b)


LEI


213800SSURRJBX85SQ91
 




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
 
Identification code


Ordinary Shares of 5 pence each in Silence Therapeutics plc
 
 
 
ISIN for Silence Therapeutics plc Ordinary Shares:
GB00B9GTXM62
 




b)


Nature of the transaction


Purchase of Ordinary Shares in Silence Therapeutics plc 
 




c)


Prices(a) and volume(s)


 



Price


Volume




£4.00


1,250



 
 




d)


Aggregated information
- Aggregated volume
- Price


 
1,250 Ordinary Shares
£5,000.00




e)


Date of the transaction


9 October 2020




f)


Place of the transaction


London Stock Exchange, AIM
 



 



1.


Details of the person discharging managerial responsibilities (PDMR) / person closely associated




a)


Name


James Ede-Golightly
 




2.


Reason for the notification




a)


Position / status


Non-Executive Director
 




b)


Initial notification / Amendment


Initial notification




3.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Silence Therapeutics plc
 




b)


LEI


213800SSURRJBX85SQ91
 




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
 
Identification code


Ordinary Shares of 5 pence each in Silence Therapeutics plc
 
 
 
ISIN for Silence Therapeutics plc Ordinary Shares:
GB00B9GTXM62
 




b)


Nature of the transaction


Purchase of Ordinary Shares in Silence Therapeutics plc 
 




c)


Prices(a) and volume(s)


 



Price


Volume




£4.0875


3,000



 
 




d)


Aggregated information
- Aggregated volume
- Price


 
3,000 Ordinary Shares
£12,262.50




e)


Date of the transaction


8 October 2020




f)


Place of the transaction


London Stock Exchange, AIM
 



 



1.


Details of the person discharging managerial responsibilities (PDMR) / person closely associated




a)


Name


Dr. Giles Campion
 




2.


Reason for the notification




a)


Position / status


Executive Director
 




b)


Initial notification / Amendment


Initial notification




3.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Silence Therapeutics plc
 




b)


LEI


213800SSURRJBX85SQ91
 




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
 
Identification code


Ordinary Shares of 5 pence each in Silence Therapeutics plc
 
 
 
ISIN for Silence Therapeutics plc Ordinary Shares:
GB00B9GTXM62
 




b)


Nature of the transaction


Purchase of Ordinary Shares in Silence Therapeutics plc 
 




c)


Prices(a) and volume(s)


 



Price


Volume




£4.04


4,945



 
 




d)


Aggregated information
- Aggregated volume
- Price


 
4,945 Ordinary Shares
£19,977.80




e)


Date of the transaction


9 October 2020




f)


Place of the transaction


London Stock Exchange, AIM
 



 
 
 
Enquiries:
 



Silence Therapeutics plc
 Gem Hopkins, Head of IR & Corporate Communications


Tel:  +1 (646) 637-3208




 
Investec Bank plc (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence
 


 
Tel:  +44 (0) 20 7597 5970




European IR
Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com 
 


Tel: +44 (0) 20 3709 5700




US IR
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
 


 Tel: +1 (443) 213-0505



 
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing a C3 targeting programme, SLN500, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases.  Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHBSBDGLSBDGGD